JNJ · Categories · M&A
JNJ - Mergers and acquisitions
Johnson & Johnson (JNJ) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for JNJ
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program
- Johnson & Johnson Completes Acquisition of V-WaveAdds V-Wave's Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech's Position in Cardiovascular Disease Johnson & Johnson1 (NYSE:JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson MedTech's position in cardiovascular disease and provides an even greater opportunity to tackle heart failure, one of the most pressing unmet medical needs in healthcare today. It f
- Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases Johnson & Johnson1 (NYSE:JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter Phase 2 studies in atopic dermatitis (AD), targets two clini
- Johnson & Johnson Completes Acquisition of Proteologix, Inc.Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic dermatitis and other immune-mediated diseases Johnson & Johnson (NYSE:JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024. "We look forward to continuing the development of PX-128 and PX-130 alongside the Proteologix team as they join Johnson & Johnson," said
- Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic DermatitisJ&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the Company has entered into a definitive agreement whe
- Johnson & Johnson Completes Acquisition of AmbrxAcquisition strengthens Johnson & Johnson's commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics Johnson & Johnson (NYSE:JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The transaction will be accounted for as a busine
- Johnson & Johnson MedTech Acquires Laminar, Inc.Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar joins Johnso
- Surgical Sutures Industry is Projected to Achieve a Global Market Size of US$ 6.5 Bn by 2031- Exclusive Report By Fact.MRROCKVILLE, Md., March 21, 2022 (GLOBE NEWSWIRE) -- According to a recently published Fact.MR report, the global Surgical Sutures market is projected to grow at a compound annual rate (CAGR) of 5.6% between 2021 and 2031. The market is expected to reach US$ 6.5 Bn by the end of 2031. The demand for Surgical Sutures is expected to rise over the forecast period and the market is projected to gain a global market size worth of US$ 4.4 Bn by 2021. Future expansion prospects are also being influenced by the increase in cardiovascular surgeries. According to W.H.O, CVDs claim nearly 18 million lives annually, with over 80% of deaths arising due to heart attacks and strokes. Also, as of August 2
- Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year ResultsNEW BRUNSWICK, N.J., Jan. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. "Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic," said Alex Gorsky, Chairman and Chief Executive Officer. "I'm incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the fight against COVID-19.
- Researchers Seek to Better Understand Psychedelics' Role in New TherapiesNEW YORK, Jan. 12, 2021 /PRNewswire/ -- Psychedelics are slowly becoming more acceptable as a legitimate treatment option for various anxiety and depression related mental illnesses. Depression is one of the most common chronic neurological disorders in modern society. It is estimated that over 250 million people suffer from some form of depression around the world. And, according to a report by Research and Markets, the U.S. reported a sharp increase (~20%) in the number of prescriptions for antidepressants and anti-anxiety drugs during the global lockdown enforced to curb the spread of the pandemic. Furthermore, the World Health Organization indicated that the major barriers to effectiv